spoke to simon
the 'close out' costs have inflated the costs for Q4 which will not be replicated in q1-q2. By closing out in q4 they have more data to be able to go to the FDA with re 2 x 2 and BT etc i believe. The issue is clearly that even assuming they are sure on their forecasts and they get their R+D, they dont have a lot of cash by end June
Paul has publicly stated a regional deal by H1... sadly here i think almost everything rests on that.
They will soon i hope confirm 2 x 2. Let's hope they try for any get breakthrough. Let's hope they get an MPS deal. But ultimately they need a china deal to get the shares to 65c to exercise the options to finish the trials without further funding.
MPS - see the reason for the delay. I wish they said this earlier but the reason for the delay is nothing untoward i believe.
spoke to simonthe 'close out' costs have inflated the...
-
- There are more pages in this discussion • 211 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |